本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 证券代码：688389 证券简称：普门科技 公告编号：2026-017 深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 剂注册证。 三、风险提示 上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后 的实际销售情况取决于未来市场的推广效果，目前尚无法预测上述产品对公司未 来业绩的具体影响。 敬请投资者理性投资，注意投资风险。 特此公告。 二、对公司的影响 促红细胞生成素（Erythropoietin，EPO）又称红细胞刺激因子，是一种内源 性酸性糖蛋白激素。EPO 能显著刺激红细胞的增殖、存活，促进造血，并且具 有促进血管生成、脑保护、肾脏保护、心脏保护、调节代谢、调节呼吸、保护消 化系统和生殖系统等作用。EPO 的分泌不足与某些形式的贫血有关，包括肾功 能衰竭贫血和终末期肾脏疾病贫血，而其它 ...

格隆汇2月27日丨普门科技(688389.SH)公布2025年度业绩快报，2025年度，公司实现营业总收入10.38亿 元，同比减少9.60%；实现归属于母公司所有者的净利润1.86亿元，同比减少46.12%；实现归属于母公 司所有者的扣除非经常性损益的净利润1.66亿元，同比减少49.28%。 2025年，受国内医保支付改革等行业政策影响，部分产品价格有所下调，公司国内业务收入与去年同期 相比有所下降；国际营销业务稳定增长，区域覆盖、本地化服务及市场准入工作持续推进。公司始终坚 持"聚焦主业"的发展战略，深耕体外诊断、临床医疗、皮肤医美、消费者健康市场，继续保持研发、营 销投入，不断丰富产品序列、深入拓展市场，努力提升公司的综合竞争力。 ...

证券日报网讯 2月27日，普门科技发布公告称，公司2025年度实现营业总收入103783.10万元，实现归属 于母公司所有者的净利润18609.47万元。 （文章来源：证券日报） ...

每经头条（nbdtoutiao）——中美大反转，中国AI调用量首超美国，A股嗨了，多板块掀涨停潮！华尔 街知名分析师：中国算力路径颠覆传统认知 （记者 曾健辉） 每经AI快讯，普门科技2月27日晚间发布2025年度业绩快报，营业收入约10.38亿元，同比减少9.6%；归 属于上市公司股东的净利润约1.86亿元，同比减少46.12%；基本每股收益0.43元，同比减少46.91%。 ...

新京报贝壳财经讯 2月27日，普门科技发布业绩快报，2025年度实现营业总收入10.38亿元，同比下降 9.60%；净利润1.86亿元，同比下降46.12%。2025年，受国内医保支付改革等行业政策影响，部分产品 价格有所下调，公司国内业务收入与去年同期相比有所下降；国际营销业务稳定增长，区域覆盖、本地 化服务及市场准入工作持续推进。 编辑 王进雨 ...

证券代码：688389 证券简称：普门科技 公告编号：2026-016 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 103,783.10 | 114,803.78 | -9.60 | | 营业利润 | 18,227.93 | 37,767.55 | -51.74 | | 利润总额 | 18,336.33 | 37,942.95 | -51.67 | | 归属于母公司所有者的 净利润 | 18,609.47 | 34,539.15 | -46.12 | | 归属于母公司所有者的 扣除非经常性损益的净 | 16,643.18 | 32,814.49 | -49.28 | | 利润 | | | | | 基本每股收益（元） | 0.43 | 0.81 | -46.91 | | 加权平均净资产收益率 | 8.97% | 18.20% | 减少 9.23 个百 | | | | | 分点 | | | 本报告期末 | 本报告期初 | 增减变动幅度 （％） | | 总资产 | 279,089.1 ...

普门科技发布业绩快报，2025年度实现营业总收入10.38亿元，同比下降9.60%；净利润1.86亿元，同比 下降46.12%。2025年，受国内医保支付改革等行业政策影响，部分产品价格有所下调，公司国内业务 收入与去年同期相比有所下降；国际营销业务稳定增长，区域覆盖、本地化服务及市场准入工作持续推 进。 ...

Core Insights - The core viewpoint of the article highlights the growing popularity of spectral therapy technology due to its non-drug, non-invasive, and low side-effect characteristics, leading to increased market penetration from professional medical institutions to home and personal consumption scenarios [1] Industry Overview - Spectral therapy devices utilize specific wavelengths (0.4-3.6μm) to irradiate the human body, achieving therapeutic purposes through photothermal effects, photochemical actions, and biological stimulation [2] - Common product names include visible light therapy devices, photon therapy devices, and red/blue light therapy devices [2] Market Size - The market size of China's spectral therapy device industry is projected to reach 244 million yuan in 2024, with a year-on-year growth of 3.83%, driven by the expansion of medical beauty demand, grassroots medical equipment upgrade policies, and consumption upgrades [8][9] Key Companies - Shenzhen Pumen Technology Co., Ltd. has obtained Class II medical device registration for its spectral therapy devices, covering multiple wavelengths [9] - Ningbo David Medical Co., Ltd. specializes in neonatal jaundice treatment devices using patented spectral technology [10] Industry Development Trends 1. **Technological Integration and Innovation**: The industry is transitioning from single-wavelength output to multi-spectral dynamic combinations, integrating AI for personalized treatment plans [11] 2. **Application Scenario Extension**: The use of spectral therapy devices is expanding from cosmetic applications to serious medical treatments, including tumor adjuvant therapy and chronic pain management [12] 3. **Industry Structure Reconstruction**: The industry is experiencing consolidation, with stricter regulations leading to increased market share for leading companies, while smaller brands may exit due to insufficient technological investment [13]

Core Insights - The digital PCR (dPCR) technology is emerging as a significant advancement in nucleic acid detection, providing more precise and sensitive methods for quantitative analysis, addressing limitations of traditional PCR methods [1][10] - The Chinese digital PCR market is projected to grow from 1.584 billion yuan in 2019 to 8.815 billion yuan by 2025, with a compound annual growth rate (CAGR) of 33.1% [1][10] - The growth is driven by technological advantages and supportive national policies, with increasing recognition of its value among researchers and clinicians [1][10] Industry Overview - Digital PCR is categorized into droplet digital PCR (ddPCR) and chip digital PCR (cdPCR), allowing for absolute quantification without relying on standard curves, suitable for single-cell analysis and early cancer diagnosis [3][4] - The technology offers significant advantages over traditional PCR, including higher sensitivity, accuracy, and better tolerance to complex samples [4][5] Market Dynamics - The digital PCR industry is supported by a robust supply chain, with upstream components including essential biological materials and core parts like optical and fluid control components [6] - The midstream involves the research, production, and sales of digital PCR devices, with notable domestic companies like New Yi Biological and Zhenzhun Biological emerging as competitors [6][7] Application Areas - Digital PCR is utilized in various fields, including clinical diagnostics for pathogen detection, research for gene expression analysis, food safety testing, and agricultural applications [7][8] - In clinical settings, it plays a crucial role in early disease diagnosis and monitoring, particularly in oncology and infectious diseases [8] Competitive Landscape - The digital PCR market in China has seen the emergence of several domestic companies, with 16 manufacturers winning bids in 2024, of which 11 are local brands [12][12] - New Yi Biological and Linghang Gene lead in market share, with respective bid shares of 20% and 17.14% [12] Future Trends - Continuous technological innovation is expected to enhance detection efficiency and reduce costs, with advancements in multi-color fluorescence detection and microfluidic chip technology [16][17] - Collaboration among upstream suppliers, midstream manufacturers, and downstream application sectors will foster a synergistic development environment [17] - There is a growing focus on expanding into international markets, with domestic companies aiming to enhance their global presence and competitiveness [18][19]

普门科技公告称，为防范汇率波动风险，提高外汇资金使用效率，公司及子公司拟开展额度不超5亿元 人民币或等值外币的外汇衍生品交易业务，期限自董事会审议通过之日起12个月内，额度可循环滚动使 用。预计动用交易保证金和权利金上限0.5亿元，资金为自有或自筹。交易品种包括远期结售汇等，交 易对方为有资格的金融机构。董事会已审议通过该议案，无需提交股东会。公司已制定制度控制风险， 将按会计准则进行会计处理。 ...